Search

Your search keyword '"Osoba, D."' showing total 385 results
Start Over Author "Osoba, D."

Refine your results

more »

more »

more »

more »
385 results on '"Osoba, D."'

2. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

Author

Yung, WKA, Albright, RE, Olson, J, Fredericks, R, Fink, K, Prados, MD, Brada, M, Spence, A, Hohl, RJ, Shapiro, W, Glantz, M, Greenberg, H, Selker, RG, Vick, NA, Rampling, R, Friedman, H, Phillips, P, Bruner, J, Yue, N, Osoba, D, Zaknoen, S, and Levin, VA

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Clinical Trials and Supportive Activities, Neurosciences, Rare Diseases, Brain Cancer, Clinical Research, Brain Disorders, Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Agents, Antineoplastic Agents, Alkylating, Brain Neoplasms, Dacarbazine, Disease-Free Survival, Female, Glioblastoma, Gliosarcoma, Humans, Male, Middle Aged, Procarbazine, Prognosis, Quality of Life, Recurrence, Temozolomide, Time Factors, malignant glioma, temozolomide, procarbazine, glioblastoma multiforme, Public Health and Health Services, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

A randomized, multicentre, open-label, phase II study compared temozolomide (TMZ), an oral second-generation alkylating agent, and procarbazine (PCB) in 225 patients with glioblastoma multiforme at first relapse. Primary objectives were to determine progression-free survival (PFS) at 6 months and safety for TMZ and PCB in adult patients who failed conventional treatment. Secondary objectives were to assess overall survival and health-related quality of life (HRQL). TMZ was given orally at 200 mg/m(2)/day or 150 mg/m(2)/day (prior chemotherapy) for 5 days, repeated every 28 days. PCB was given orally at 150 mg/m(2)/day or 125 mg/m(2)/day (prior chemotherapy) for 28 days, repeated every 56 days. HRQL was assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30 [+3]) and the Brain Cancer Module 20 (BCM20). The 6-month PFS rate for patients who received TMZ was 21%, which met the protocol objective. The 6-month PFS rate for those who received PCB was 8% (P = 0.008, for the comparison). Overall PFS significantly improved with TMZ, with a median PFS of 12.4 weeks in the TMZ group and 8.32 weeks in the PCB group (P = 0.0063). The 6-month overall survival rate for TMZ patients was 60% vs. 44% for PCB patients (P = 0.019). Freedom from disease progression was associated with maintenance of HRQL, regardless of treatment received. TMZ had an acceptable safety profile; most adverse events were mild or moderate in severity.

Published
2000

5. Impact of Lymphopenia on Survival for Elderly Patients with Glioblastoma: A Secondary Analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) Randomized Clinical Trial

Author

Song, A.J., primary, Ding, K., additional, Laperriere, N.J., additional, Perry, J., additional, Mason, W.P., additional, Winch, C., additional, O'Callaghan, C.J., additional, Menten, J., additional, Brandes, A.A., additional, Phillips, C., additional, Fay, M.F., additional, Nishikawa, R., additional, Osoba, D., additional, Cairncross, G., additional, Roa, W., additional, Wick, W., additional, and Shi, W., additional

Published
2020
Full Text
View/download PDF

25. Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G

Author

King, MT, Stockler, MR, Cella, DF, Osoba, D, Eton, DT, Thompson, J, and Eisenstein, AR

Subjects
Questionnaires, Male, Evidence-Based Medicine, Psychometrics, Epidemiology, Guidelines as Topic, Neoplasms, Surveys and Questionnaires, Quality of Life, Humans, Health Status Indicators, Female, Epidemiologic Methods, Expert Testimony
Abstract

OBJECTIVE: To compare Cohen's guidelines for small (0.2), medium (0.5), and large (0.8) effect sizes with empirical estimates for a cancer-specific health-related quality-of-life questionnaire (HRQOL), the Functional Assessment of Cancer Therapy - General (FACT-G). METHODS: Seventy-one papers satisfied inclusion criteria for meta-analysis. Blinded to the HRQOL results, three "experts" (with expertise in interpreting the FACT-G questionnaire and managing cancer patients), predicted the relative magnitude of HRQOL mean differences. Size classes (small, medium, large) were defined in terms of relevance to clinical decision making. The experts worked independently and based their predictions on patient characteristics and clinical circumstances. Their judgments were linked with FACT-G results and inverse-variance-weighted mean effect sizes calculated for each size class. RESULTS: At least two experts were perfectly concordant and up to one was discordant by at most one size category for 833 of the mean differences; for these, weighted kappas were generally in the "substantial" range (0.60-0.79). Of these mean differences, 617 were cross-sectional; small, medium, and large mean effect sizes were physical well-being 0.42, 0.87, 1.6; functional well-being 0.37, 0.71, 1.6; emotional well-being 0.32, 0.40, no large differences; and social well-being 0.14, 0.23, no large differences. Two hundred and sixteen longitudinal mean differences yielded small and medium effect sizes: physical well-being 0.26, 0.34; functional well-being 0.14, 0.28; emotional well-being 0.27, 0.23; and social well-being 0.08, 0.01. There was virtually no evidence for large longitudinal effects. CONCLUSION: These results provide specific, evidence-based alternatives to Cohen's generic guidelines, for use in sample-size calculations for the FACT-G and interpretation of the clinical significance of effects measured with FACT-G.

Published
2009

26. Health-related quality-of-life studies of the National Cancer Institute of Canada Clinical Trials Group

Author

Osoba, D., Dancey, J., Benny Chung-Ying Zee, Myles, J., and Pater, J.

Subjects
Canada, Clinical Trials, Phase III as Topic, Neoplasms, Quality of Life, Humans
Abstract

Since 1989, the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) has been successful in implementing and completing health-related quality-of-life (HQL) assessments as part of phase III clinical trials. Compliance rates for completing HQL instruments remain high, with a minimal amount of missing data. It is believed that this success is attributable not only to the high degree of commitment to measuring HQL by clinical trials investigators, nurses, data managers, and central office administrative staff, but also to the educational process that was instituted after the development of a CTG policy for measuring HQL. From inception to May 1995, a total of 27 clinical trials with HQL assessment have been initiated or completed. In the majority of trials, the core HQL instrument is the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). In addition to answering specific questions about HQL in these clinical trials, the trials provide the opportunity to do research into the measurement of HQL. Thus, current clinical trials include research questions about the appropriate timing of assessments, the reliability and validity of the QLQ-C30 and other instruments, the role of HQL data in assessing toxicity, and the significance of the results of HQL assessments. It is anticipated that this activity not only will be a rich source of information about the effects of cancer and its treatment on HQL but also will lead to improvements in measuring HQL in oncology.

Published
1996

27. CN3 Validation Study Of The Baseline Quality Of Life As A Prognostic Indicator Of SURVIVAL: A Pooled Analysis Of Individual Patient Data From NCIC Clinical Trials

Author

Ediebah, D.E., primary, Quinten, C., additional, Coens, C., additional, Zikos, E., additional, Ringash, J., additional, Gotay, C., additional, Flechtner, H.H., additional, Osoba, D., additional, King, M., additional, Cleeland, C., additional, Greimel, E., additional, Reeve, B.B., additional, Taphoorn, M., additional, Schmucker-Von Koch, J., additional, Weis, J., additional, and Bottomley, A., additional

Published
2011
Full Text
View/download PDF

29. Effect of time windows in analysis of health-related quality-of-life (HRQOL) outcomes.

Author

Quinten, C., primary, Coens, C., additional, Maringwa, J., additional, Martinelli, F., additional, Ringash, J., additional, Osoba, D., additional, Reeve, B. B., additional, King, M., additional, Cleeland, C. S., additional, Flechtner, H., additional, Gotay, C., additional, Greimel, E., additional, Taphoorn, M. J. B., additional, Weis, J., additional, Schmucker-Von Koch, J., additional, Schmoll, H., additional, and Bottomley, A., additional

Published
2011
Full Text
View/download PDF

31. PCN127 MINIMAL CLINICALLY MEANINGFUL DIFFERENCES FOR THE EORTC QLQ-C30 AND EORTC QLQ-BN20 SCALES IN BRAIN CANCER PATIENTS

Author

Maringwa, J, primary, Quinten, C, additional, King, M, additional, Ringash, J, additional, Osoba, D, additional, Coens, C, additional, Martinelli, F, additional, Cleeland, C, additional, Flechtner, H, additional, Gotay, C, additional, Greimel, E, additional, Taphoorn, M, additional, Reeve, B, additional, Schmucker-Von, Koch J, additional, Weis, J, additional, Van Den Bent, MJ, additional, Stupp, R, additional, and Bottomley, A, additional

Published
2010
Full Text
View/download PDF

34. PCN90 A METHODOLOGICAL INVESTIGATION TO DEFINE A CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE

Author

Quinten, C, primary, Martinelli, F, additional, Coens, C, additional, Maringwa, J, additional, Cleeland, C, additional, Fechtner, H, additional, Gotay, C, additional, Greimel, E, additional, King, M, additional, Osoba, D, additional, Taphoorn, MJB, additional, Reeve, B, additional, Ringash, J, additional, Schmucker-Von Koch, J, additional, Weis, J, additional, and Bottomley, A, additional

Published
2009
Full Text
View/download PDF

35. The EORTC QLQ-BN20 questionnaire for assessing the health-related quality of life (HRQoL) in brain cancer patients: A phase IV validation study on behalf of the EORTC QLG, BCG, ROG, NCIC-CTG

Author

Taphoorn, M. J., primary, Claassens, L., additional, Aaronson, N. K., additional, Coens, C., additional, Mauer, M., additional, Osoba, D., additional, Stupp, R., additional, Mirimanoff, R., additional, Van den Bent, M. J., additional, and Bottomley, A., additional

Published
2008
Full Text
View/download PDF

38. The prognostic value of health-related quality-of-life data in predicting survival in glioblastoma cancer patients: results from an international randomised phase III EORTC Brain Tumour and Radiation Oncology Groups, and NCIC Clinical Trials Group study

Author

Mauer, M, primary, Stupp, R, additional, Taphoorn, M J B, additional, Coens, C, additional, Osoba, D, additional, Marosi, C, additional, Wong, R, additional, de Witte, O, additional, Cairncross, J G, additional, Efficace, F, additional, Mirimanoff, R O, additional, Forsyth, P, additional, van den Bent, M J, additional, Weller, M, additional, and Bottomley, A, additional

Published
2007
Full Text
View/download PDF

48. Methodological and statistical issues of quality of life (QoL) and economic evaluation in cancer clinical trials: report of a workshop

Author

Neymark, N, primary, Kiebert, W, additional, Torfs, K, additional, Davies, L, additional, Fayers, P, additional, Hillner, B, additional, Gelber, R, additional, Guyatt, G, additional, Kind, P, additional, Machin, D, additional, Nord, E, additional, Osoba, D, additional, Revicki, D, additional, Schulman, K, additional, and Simpson, K, additional

Published
1998
Full Text
View/download PDF

49. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group.

Author

Latreille, J, primary, Pater, J, additional, Johnston, D, additional, Laberge, F, additional, Stewart, D, additional, Rusthoven, J, additional, Hoskins, P, additional, Findlay, B, additional, McMurtrie, E, additional, Yelle, L, additional, Williams, C, additional, Walde, D, additional, Ernst, S, additional, Dhaliwal, H, additional, Warr, D, additional, Shepherd, F, additional, Mee, D, additional, Nishimura, L, additional, Osoba, D, additional, and Zee, B, additional

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results